S. Collins

发表

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

H. Stellbrink, P. Sax, H. Albrecht, 2019, The lancet. HIV.

Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.

K. White, C. Orkin, C. Kityo, 2021, Journal of acquired immune deficiency syndromes.

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials†

H. Stellbrink, M. Das, E. Daar, 2018, HIV medicine.

High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I

K. White, P. Sax, J. Gallant, 2022, AIDS.

Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight

K. White, M. Das, L. A. Burns-Naas, 2020, PloS one.

1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis

D. Asmuth, J. Slim, J. Eron, 2020, Open Forum Infectious Diseases.

Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients

R. Shafer, P. Grant, S. Collins, 2015, Drugs.

A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans

A. Zolopa, P. Grant, S. Nsanzimana, 2016, Open forum infectious diseases.

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide

D. Ward, P. Sax, A. Cheng, 2018, AIDS.

Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals

M. Kozal, H. Günthard, S. Little, 2021, AIDS.

Integrating Integrase Inhibitors Into an Antiretroviral Regimen

A. Zolopa, P. Grant, S. Collins, 2014, Current Treatment Options in Infectious Diseases.

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

H. Jessen, R. Grant, K. Mounzer, 2020, The Lancet.

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.

D. Podzamczer, H. Stellbrink, P. Sax, 2020, The lancet. HIV.

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study

M. Saag, M. Ramgopal, D. Brainard, 2021, Journal of acquired immune deficiency syndromes.

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-Existing NRTI Resistance.

K. White, Ross Martin, Hal Martin, 2020, Journal of acquired immune deficiency syndromes.

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

D. Ward, P. Sax, Y. Yazdanpanah, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

Y. Yazdanpanah, A. Antinori, A. Clarke, 2019, The lancet. HIV.